Compass Pathways falls after earnings miss, Phase 3 catalysts intact
$200M warrant exercises extend runway into 2028 as psilocybin therapy advances toward FDA submission
Compass Pathways shares declined in Tuesday trading after the mental health company reported a wider-than-expected quarterly loss, though analysts emphasized that core operational metrics improved and key regulatory milestones for its psychedelic therapy remain on track.
The company reported a fourth-quarter loss of $1.00 per share, missing the analyst consensus estimate of $0.37, according to the company's earnings release. The net loss widened to $93.9 million compared with $43.3 million in the same period a year earlier.
However, the headline loss was driven primarily by a $38.2 million non-cash mark-to-market adjustment related to warrants, rather than deteriorating operations. Research and development spending actually declined to $29.9 million from $32.1 million, indicating improved efficiency as the company advances its lead program through late-stage development.
The earnings miss overshadowed significant strategic progress on Compass's flagship COMP360 program, a synthetic psilocybin formulation for treatment-resistant depression. The company has two positive Phase 3 trials and is pursuing a rolling New Drug Application submission with the Food and Drug Administration, with completion expected in the fourth quarter of 2026.
"Compass Pathways continues rolling NDA submission for COMP360 for TRD, anticipating completion in Q4 2026," the earnings report stated. Critical 26-week data from the COMP006 trial, which will support the regulatory filing, is expected early in the third quarter.
The company's financial position strengthened considerably in February when warrant exercises generated approximately $200 million, extending its cash runway into 2028. According to the company's announcement, the financing provides sufficient resources to complete the NDA submission and support operations through key regulatory milestones.
Despite Tuesday's decline, analyst sentiment remains broadly positive. MarketBeat data shows 11 analysts rate the stock a buy or strong buy, with only one hold recommendation and no sell ratings. The average price target stands at $21.92, representing substantial upside from current levels around $5.34.
The high beta of 1.98 indicates significant volatility in Compass shares, which have traded in a 52-week range of $2.25 to $8.90. The company's market capitalization stands at approximately $614 million.
Treatment-resistant depression represents a substantial unmet medical need, with existing therapies failing many patients. COMP360, if approved, would be among the first psychedelic-derived treatments to reach the U.S. market under a regulatory pathway specifically designed for these novel therapies.
Investors will focus on the upcoming COMP006 data readout in the coming months as the next significant catalyst. The 26-week results are expected to provide critical evidence of durability for COMP360's treatment effect, which is considered essential for regulatory approval and commercial positioning.
The FDA meeting to confirm the NDA rolling submission process represents another near-term milestone that could provide clarity on the regulatory pathway and potential approval timeline. With cash now secured through 2028, the company can focus on execution without the immediate pressure of raising additional capital.